These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 23382304

  • 1. DEND syndrome due to V59A mutation in KCNJ11 gene: unresponsive to sulfonylureas.
    Itoh S, Matsuoka H, Yasuda Y, Miyake N, Suzuki K, Yorifuji T, Sugihara S.
    J Pediatr Endocrinol Metab; 2013; 26(1-2):143-6. PubMed ID: 23382304
    [Abstract] [Full Text] [Related]

  • 2. Permanent neonatal diabetes mellitus caused by a novel mutation in the KCNJ11 gene.
    Doneray H, Houghton J, Tekgunduz KS, Balkir F, Caner I.
    J Pediatr Endocrinol Metab; 2014 Mar; 27(3-4):367-71. PubMed ID: 24150202
    [Abstract] [Full Text] [Related]

  • 3. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation.
    Ješić MM, Ješić MD, Maglajlić S, Sajić S, Necić S.
    Diabetes Res Clin Pract; 2011 Jan; 91(1):e1-3. PubMed ID: 21056492
    [Abstract] [Full Text] [Related]

  • 4. A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain.
    Shimomura K, Hörster F, de Wet H, Flanagan SE, Ellard S, Hattersley AT, Wolf NI, Ashcroft F, Ebinger F.
    Neurology; 2007 Sep 25; 69(13):1342-9. PubMed ID: 17652641
    [Abstract] [Full Text] [Related]

  • 5. KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features.
    Gloyn AL, Diatloff-Zito C, Edghill EL, Bellanné-Chantelot C, Nivot S, Coutant R, Ellard S, Hattersley AT, Robert JJ.
    Eur J Hum Genet; 2006 Jul 25; 14(7):824-30. PubMed ID: 16670688
    [Abstract] [Full Text] [Related]

  • 6. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.
    Mlynarski W, Tarasov AI, Gach A, Girard CA, Pietrzak I, Zubcevic L, Kusmierek J, Klupa T, Malecki MT, Ashcroft FM.
    Nat Clin Pract Neurol; 2007 Nov 25; 3(11):640-5. PubMed ID: 17982434
    [Abstract] [Full Text] [Related]

  • 7. Successful transition to sulfonylurea in neonatal diabetes, developmental delay, and seizures (DEND syndrome) due to R50P KCNJ11 mutation.
    Peña-Almazan S.
    Diabetes Res Clin Pract; 2015 Apr 25; 108(1):e18-20. PubMed ID: 25678012
    [Abstract] [Full Text] [Related]

  • 8. Molecular Genetics, Clinical Characteristics, and Treatment Outcomes of KATP-Channel Neonatal Diabetes Mellitus in Vietnam National Children's Hospital.
    Ngoc CTB, Dien TM, De Franco E, Ellard S, Houghton JAL, Lan NN, Thao BP, Khanh NN, Flanagan SE, Craig ME, Dung VC.
    Front Endocrinol (Lausanne); 2021 Apr 25; 12():727083. PubMed ID: 34566892
    [Abstract] [Full Text] [Related]

  • 9. Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene.
    Al-Mahdi M, Al Mutair A, Al Balwi M, Hussain K.
    Ann Saudi Med; 2010 Apr 25; 30(2):162-4. PubMed ID: 20220270
    [Abstract] [Full Text] [Related]

  • 10. Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene.
    Tonini G, Bizzarri C, Bonfanti R, Vanelli M, Cerutti F, Faleschini E, Meschi F, Prisco F, Ciacco E, Cappa M, Torelli C, Cauvin V, Tumini S, Iafusco D, Barbetti F, Early-Onset Diabetes Study Group of the Italian Society of Paediatric Endocrinology and Diabetology.
    Diabetologia; 2006 Sep 25; 49(9):2210-3. PubMed ID: 16816952
    [No Abstract] [Full Text] [Related]

  • 11. Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.
    Lau E, Correia C, Freitas P, Nogueira C, Costa M, Saavedra A, Costa C, Carvalho D, Fontoura M.
    Arch Endocrinol Metab; 2015 Dec 25; 59(6):559-61. PubMed ID: 26331221
    [Abstract] [Full Text] [Related]

  • 12. Sulfonylrea treatment in permanent neonatal diabetes due to G53D mutation in the KCNJ11 gene: improvement in glycemic control and neurological function.
    Gurgel LC, Crispim F, Noffs MH, Belzunces E, Rahal MA, Moisés RS.
    Diabetes Care; 2007 Nov 25; 30(11):e108. PubMed ID: 17965292
    [No Abstract] [Full Text] [Related]

  • 13. Transfer to sulphonylurea therapy in adult subjects with permanent neonatal diabetes due to KCNJ11-activating [corrected] mutations: evidence for improvement in insulin sensitivity.
    Malecki MT, Skupien J, Klupa T, Wanic K, Mlynarski W, Gach A, Solecka I, Sieradzki J.
    Diabetes Care; 2007 Jan 25; 30(1):147-9. PubMed ID: 17192350
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM.
    Mohamadi A, Clark LM, Lipkin PH, Mahone EM, Wodka EL, Plotnick LP.
    Pediatr Diabetes; 2010 May 25; 11(3):203-7. PubMed ID: 19686306
    [Abstract] [Full Text] [Related]

  • 16. Permanent neonatal diabetes mellitus due to KCNJ11 mutation in a Portuguese family: transition from insulin to oral sulfonylureas.
    Dupont J, Pereira C, Medeira A, Duarte R, Ellard S, Sampaio L.
    J Pediatr Endocrinol Metab; 2012 May 25; 25(3-4):367-70. PubMed ID: 22768671
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
    Bowman P, Sulen Å, Barbetti F, Beltrand J, Svalastoga P, Codner E, Tessmann EH, Juliusson PB, Skrivarhaug T, Pearson ER, Flanagan SE, Babiker T, Thomas NJ, Shepherd MH, Ellard S, Klimes I, Szopa M, Polak M, Iafusco D, Hattersley AT, Njølstad PR, Neonatal Diabetes International Collaborative Group.
    Lancet Diabetes Endocrinol; 2018 Aug 25; 6(8):637-646. PubMed ID: 29880308
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Sulfonylurea in the treatment of neonatal diabetes mellitus children with heterogeneous genetic backgrounds.
    Zhang M, Chen X, Shen S, Li T, Chen L, Hu M, Cao L, Cheng R, Zhao Z, Luo F.
    J Pediatr Endocrinol Metab; 2015 Jul 25; 28(7-8):877-84. PubMed ID: 25781672
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.